Insulet Corporation — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; filed February 25, 2020. The filing reports annual results and unaudited quarterly data, including Q4 2019. Insulet develops and sells the Omnipod tubeless insulin-delivery system; Omnipod DASH launched in the U.S. during 2019. The company also supplies drug-delivery products, principally for Amgen’s Neulasta Onpro kit.
Financial performance and liquidity
| Metric | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $738.2 million | $563.8 million | +31% |
| Gross profit / margin | $480.3 million / 65.1% | $370.2 million / 65.7% | Profit +30%; margin down 0.6 points |
| Operating income | $50.0 million | $27.4 million | +82% |
| Net income | $11.6 million | $3.3 million | +252% |
| Diluted EPS | $0.19 | $0.05 | Increased |
| Cash from operations | $98.4 million | $35.9 million | Increased |
| Capital expenditures | $163.7 million | $157.4 million | Increased |
U.S. Omnipod revenue rose 30% to $420.4 million; international Omnipod revenue increased 47% to $253.1 million. Drug-delivery revenue declined 5% to $64.7 million. Gross-margin pressure from U.S. manufacturing start-up costs and product mix partly offset favorable channel and geographic mix. Operating expenses rose 26% to $430.3 million, including R&D of $129.7 million, sales and marketing of $185.1 million, and G&A of $115.5 million.
Q4 2019: Revenue was $209.4 million, gross profit $134.1 million, net income $5.0 million, and diluted EPS $0.08. In Q4 2018, the respective figures were $164.9 million, $110.3 million, $9.9 million, and $0.16. Thus, revenue and gross profit grew year over year, while quarterly net income and EPS declined.
At year-end, cash and cash equivalents were $213.7 million, short-term investments $162.4 million, and long-term investments $58.4 million. The filing states cash, cash equivalents and short-term investments totaled $376.1 million and were expected, with projected sales cash flows, to support operations through at least the end of 2020. Convertible-note principal totaled $1.2025 billion; carrying value, net of discounts and issuance costs, was $887.9 million. Total assets were $1.143 billion, total liabilities $1.067 billion, and stockholders’ equity $75.9 million.
Material changes and unusual items
- Revenue increased 31%, led by Omnipod growth, expanded U.S. pharmacy-channel sales, and higher international sales following the move to direct European operations. Approximately 65% of Omnipod sales were through intermediaries; sales outside the U.S. were 34% of revenue.
- Insulet issued $800 million of 0.375% convertible notes due 2026 and used proceeds in part to repurchase its 1.25% notes due 2021. The repurchase resulted in an $8.7 million extinguishment loss. The company also paid $85.4 million for capped calls intended to reduce potential dilution.
- The new Acton, Massachusetts automated manufacturing facility began production. Cumulative investment was approximately $320 million; property, plant and equipment rose to $399.4 million from $258.4 million. Inventory increased to $101.0 million from $71.4 million, partly to support the facility start-up and demand.
- Cash from operations improved, but operating cash flow was below capital spending. Management attributed working-capital use mainly to increased inventory and prepaid expenses, partly offset by higher payables and accrued liabilities.
- An arbitration with a former European distributor concerns fees following the 2018 contract expiration. Insulet estimated the final aggregate fee could range from $5 million to $55 million; $2.7 million was accrued at year-end.
Outlook, commentary and principal risks
Management expected strong Omnipod revenue growth in 2020, driven by market penetration, DASH, pharmacy-channel expansion and broader payor coverage, partly offset by lower drug-delivery revenue. It expected 2020 gross margin to be broadly consistent with 2019, with manufacturing improvements and channel mix offset by continued U.S. facility ramp costs. R&D, sales and marketing, G&A, interest expense and capital expenditures were each expected to increase or remain elevated as described in the filing. Management planned to begin Omnipod Horizon’s U.S. launch in the second half of 2020, while cautioning that it was not expected to contribute meaningfully to 2020 growth. These are forward-looking expectations, not guaranteed results.
- Execution and yield at the new U.S. facility, manufacturing capacity expansion, and reliance on Flex’s China facility and certain sole-source components.
- Dependence on Omnipod sales, reimbursement and payor coverage; competition from conventional pumps, automated delivery systems and lower-cost multiple daily injections.
- Product safety, quality, regulatory clearance, clinical-trial and commercialization risks, including timing of Horizon development and launch.
- Convertible debt service, refinancing and potential dilution; management noted financing needs could arise, including to repay notes.
- Foreign-exchange exposure, international operations, privacy and cybersecurity risks, and evolving healthcare and data-protection regulations.
- Customer concentration: Cardinal Health and affiliates represented 11% of 2019 revenue; no other named customer exceeded 10% that year.
The auditor gave an unqualified opinion on the financial statements and concluded internal control over financial reporting was effective. Critical audit matters included drug-delivery revenue recognition and the convertible-note issuance and repurchase. The filing also describes prior shareholder litigation settlements, with certain fee approvals still pending; management did not expect ordinary-course litigation to have a material adverse effect.
Important facts for investors to verify
- Whether Omnipod and DASH growth, pharmacy-channel expansion and payor access continue at a pace that supports revenue and profitability.
- Whether Acton manufacturing reaches planned capacity and reduces unit costs without quality, supply or margin disruption.
- Progress, regulatory status and actual launch timing for Omnipod Horizon, and the financial impact if delayed.
- Debt terms, cash generation, future capital requirements, conversion dilution and capacity to meet note obligations.
- Outcome and final amount of the former European distributor arbitration, compared with the disclosed $5 million–$55 million estimate.
- Whether the decline in Q4 net income versus Q4 2018 reflects timing and debt-related items or signals sustained margin or cost pressure.